PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics

SRC: A Century of Science Brought to the Clinic

(2015) Alexey Aleshin et al.   NEOPLASIA

Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression

(2012) Kiran Mahajan et al.   AMERICAN JOURNAL OF PATHOLOGY

MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks

(2011) Michael Fraser et al.   CELL CYCLE

Selective PI3Kδ inhibitors, a review of the patent literature

(2011) Peter Norman   EXPERT OPINION ON THERAPEUTIC PATENTS

IKBKE Protein Activates Akt Independent of Phosphatidylinositol 3-Kinase/PDK1/mTORC2 and the Pleckstrin Homology Domain to Sustain Malignant Transformation

(2011) Jian-Ping Guo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phosphatidic Acid Binds and StimulatesArabidopsisSphingosine Kinases

(2011) Liang Guo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation

(2011) Yi-Hung Ou et al.   MOLECULAR CELL

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer

(2011) Markus K Muellner et al.   Nature Chemical Biology

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

(2011) B N Rexer et al.   ONCOGENE

Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma

(2011) Yoram Cohen et al.   ORAL ONCOLOGY

I B kinase   and TANK-binding kinase 1 activate AKT by direct phosphorylation

(2011) X. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases

(2011) Oscar Vadas et al.   Science Signaling

Shepherding AKT and androgen receptor by Ack1 tyrosine kinase

(2010) Kiran Mahajan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Akt Contributes to Activation of the TRIF-Dependent Signaling Pathways of TLRs by Interacting with TANK-Binding Kinase 1

(2010) S. M. Joung et al.   JOURNAL OF IMMUNOLOGY

IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-κB

(2010) Hongyu Guan et al.   JOURNAL OF PATHOLOGY

Protein Tyrosine Kinase 6 Directly Phosphorylates AKT and Promotes AKT Activation in Response to Epidermal Growth Factor

(2010) Y. Zheng et al.   MOLECULAR AND CELLULAR BIOLOGY

Diverse somatic mutation patterns and pathway alterations in human cancers

(2010) Zhengyan Kan et al.   NATURE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

(2010) Jiannong Li et al.   Nature Chemical Biology

Designing selective PI3K inhibitors

(2010) Sarah Crunkhorn   NATURE REVIEWS DRUG DISCOVERY

Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations

(2010) J Lauring et al.   ONCOGENE

Emerging roles for the non-canonical IKKs in cancer

(2010) R R Shen et al.   ONCOGENE

Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation

(2010) Kiran Mahajan et al.   PLoS One

Microenvironment and Pathogenesis of Epithelial Ovarian Cancer

(2010) Antonio F. Saad et al.   Hormones & Cancer

Somatic mutations are present in all members of the AKT family in endometrial carcinoma

(2009) A Dutt et al.   BRITISH JOURNAL OF CANCER

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma

(2009) Yoram Cohen et al.   GYNECOLOGIC ONCOLOGY

Use of the Pharmacological Inhibitor BX795 to Study the Regulation and Physiological Roles of TBK1 and IκB Kinase ϵ

(2009) Kristopher Clark et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

(2009) Tim P. Green et al.   Molecular Oncology

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Corrected structure of mirin, a small-molecule inhibitor of the Mre11–Rad50–Nbs1 complex

(2009) Kristen M Garner et al.   Nature Chemical Biology

Absence of mutations in the AKT1 oncogene in glioblastomas and medulloblastomas

(2008) Ulrich Schüller et al.   ACTA NEUROPATHOLOGICA

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation

(2008) Raoul Tibes et al.   BRITISH JOURNAL OF HAEMATOLOGY

Drug-Resistant Phosphatidylinositol 3-Kinase: Guidance for the Preemptive Strike

(2008) Peter K. Vogt   CANCER CELL

Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

(2008) Eli R. Zunder et al.   CANCER CELL

In VivoAnalysis of Protein Kinase B (PKB)/Akt Regulation in DNA-PKcs-null Mice Reveals a Role for PKB/Akt in DNA Damage Response and Tumorigenesis

(2008) Banu Surucu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival

(2008) Lana Bozulic et al.   MOLECULAR CELL

A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complex

(2008) Aude Dupré et al.   Nature Chemical Biology